Page last updated: 2024-11-04

vorinostat and Invasiveness, Neoplasm

vorinostat has been researched along with Invasiveness, Neoplasm in 18 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"Rhein has antitumor and SGK1 suppression effects, although its biological activity is limited by poor bioavailability."5.56Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug. ( Chen, J; Luo, B; Pi, R; Wen, S, 2020)
"Matrigel and Collagen invasion assays were performed to evaluate the effect of several HDACi (Butyrate, Trichostatin A, Valproic acid and Vorinostat) on two human melanoma cell line invasion (A375 and HT-144)."3.83Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity. ( Andrade, R; Aréchaga, J; Arluzea, J; De Wever, O; Díaz-Núñez, M; Díez-Torre, A; Silió, M, 2016)
"Rhein has antitumor and SGK1 suppression effects, although its biological activity is limited by poor bioavailability."1.56Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug. ( Chen, J; Luo, B; Pi, R; Wen, S, 2020)
"Vorinostat has good therapeutic efficacy against primary cutaneous T-cell lymphoma in the refractory stage."1.56Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells. ( Cai, Y; He, Z; Liang, S; Xia, C, 2020)
"However, the role of Rnd1 in hepatocellular carcinoma (HCC) progression remains unclear."1.48The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. ( Chai, ZT; Jia, QA; Ma, DN; Qin, CD; Ren, ZG; Sun, HC; Tang, ZY; Wang, CH; Zhang, N; Zhang, SZ; Zhu, XD, 2018)
"Metastasis is the reason for most cancer death, and a crucial primary step for cancer metastasis is invasion of the surrounding tissue, which may be initiated by some rare tumor cells that escape the heterogeneous primary tumor."1.43Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells. ( Chen, X; Deng, Q; Feng, J; Guo, C; Huang, H; Ma, S; Shen, B; Wu, K; Wu, Z; Xia, B; Zhang, J; Zhang, K; Zhang, S; Zhu, L, 2016)
"LW479 could be a candidate drug for breast cancer prevention."1.42Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression. ( Chen, Y; Dai, F; Gao, D; He, Y; Li, J; Liu, M; Yang, F; Yi, Z; Zhang, T, 2015)
"Triple-negative breast cancer (TNBC), defined by the absence of an estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, is associated with an early recurrence of disease and poor outcome."1.39Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. ( Chen, YA; Chiou, YS; Chiu, HW; Ho, SY; Huang, WJ; Lin, P; Wang, YC; Wang, YJ; Yeh, YL, 2013)
"Re-expression of miR-34a in human pancreatic cancer stem cells (CSCs) and in human pancreatic cancer cell lines upon treatment with 5-Aza-dC and SAHA strongly inhibited the cell proliferation, cell cycle progression, self-renewal, epithelial to mesenchymal transition (EMT) and invasion."1.37Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. ( Nalls, D; Rodova, M; Shankar, S; Srivastava, RK; Tang, SN, 2011)
"High grade gliomas are aggressive cancers that are not well addressed by current chemotherapies, in large measure because these drugs do not curtail the diffuse invasion of glioma cells into brain tissue surrounding the tumor."1.36Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. ( An, Z; Choy, ML; Gluck, CB; Kaufman, LJ, 2010)
"This combined therapeutic effect on esophageal cancer epithelial-mesenchymal transition was associated with upregulation of E-cadherin protein expression."1.36Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells. ( Jones, DR; Liu, Y; Nagji, AS; Taylor, MD; Theodosakis, N, 2010)
"Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced breast cancer (LABC)."1.36Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. ( Bornmann, W; Cristofanilli, M; Hall, CS; Pal, A; Peng, Z; Pickei, R; Robertson, FM; Woodward, WA; Ye, Z, 2010)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (5.56)29.6817
2010's15 (83.33)24.3611
2020's2 (11.11)2.80

Authors

AuthorsStudies
Takahashi, N2
Takeda, K1
Imai, M1
Chen, J1
Luo, B1
Wen, S1
Pi, R1
Xia, C1
He, Z1
Cai, Y1
Liang, S1
Peela, N1
Barrientos, ES1
Truong, D1
Mouneimne, G1
Nikkhah, M1
Qin, CD1
Ma, DN1
Zhang, SZ1
Zhang, N1
Ren, ZG1
Zhu, XD1
Jia, QA1
Chai, ZT1
Wang, CH1
Sun, HC1
Tang, ZY1
Chiu, HW1
Yeh, YL1
Wang, YC1
Huang, WJ1
Chen, YA1
Chiou, YS1
Ho, SY1
Lin, P1
Wang, YJ1
Li, J1
Zhang, T1
Yang, F1
He, Y1
Dai, F1
Gao, D1
Chen, Y1
Liu, M1
Yi, Z1
Mahal, K1
Kahlen, P1
Biersack, B1
Schobert, R1
Meng, Z1
Jia, LF1
Gan, YH1
Lu, H1
Yang, XF1
Tian, XQ1
Tang, SL1
Li, LQ1
Zhao, S1
Zheng, HC1
Díaz-Núñez, M1
Díez-Torre, A1
De Wever, O1
Andrade, R1
Arluzea, J1
Silió, M1
Aréchaga, J1
Zhang, S1
Wu, K1
Feng, J1
Wu, Z1
Deng, Q1
Guo, C1
Xia, B1
Zhang, J1
Huang, H1
Zhu, L1
Zhang, K1
Shen, B1
Chen, X1
Ma, S1
Abe, F1
Kitadate, A1
Ikeda, S1
Yamashita, J1
Nakanishi, H1
Asaka, C1
Teshima, K1
Miyagaki, T1
Sugaya, M1
Tagawa, H1
An, Z1
Gluck, CB1
Choy, ML1
Kaufman, LJ1
Taylor, MD1
Liu, Y1
Nagji, AS1
Theodosakis, N1
Jones, DR1
Robertson, FM1
Woodward, WA1
Pickei, R1
Ye, Z1
Bornmann, W1
Pal, A1
Peng, Z1
Hall, CS1
Cristofanilli, M1
Nalls, D1
Tang, SN1
Rodova, M1
Srivastava, RK1
Shankar, S1
Takada, Y1
Gillenwater, A1
Ichikawa, H1
Aggarwal, BB1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer[NCT01938833]Phase 1/Phase 29 participants (Actual)Interventional2014-04-30Terminated (stopped due to Closed by Sponsor)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

18 other studies available for vorinostat and Invasiveness, Neoplasm

ArticleYear
Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
    Bioorganic & medicinal chemistry, 2013, Oct-01, Volume: 21, Issue:19

    Topics: Aminophenols; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fibrosarcoma;

2013
Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug.
    Investigational new drugs, 2020, Volume: 38, Issue:3

    Topics: Anthraquinones; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Movement; Cel

2020
Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells.
    European journal of pharmacology, 2020, May-15, Volume: 875

    Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Fem

2020
Effect of suberoylanilide hydroxamic acid (SAHA) on breast cancer cells within a tumor-stroma microfluidic model.
    Integrative biology : quantitative biosciences from nano to macro, 2017, Dec-11, Volume: 9, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diffusion;

2017
The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
    Cell death & disease, 2018, 05-01, Volume: 9, Issue:5

    Topics: Animals; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Decitabine; Epigenesis, Genet

2018
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Movem

2013
Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
    British journal of pharmacology, 2015, Volume: 172, Issue:15

    Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell

2015
4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation.
    Experimental cell research, 2015, Aug-15, Volume: 336, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proli

2015
PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition.
    Oncogene, 2016, 05-05, Volume: 35, Issue:18

    Topics: Acetylation; Animals; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Enzyme Act

2016
The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells.
    Oncotarget, 2016, Aug-30, Volume: 7, Issue:35

    Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Animals; Antineoplastic Agents; Apoptosis; Asp

2016
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
    BMC cancer, 2016, 08-22, Volume: 16

    Topics: Antineoplastic Agents; Apoptosis; Butyrates; Cadherins; Cell Line, Tumor; Gene Expression Regulation

2016
Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells.
    Oncotarget, 2016, Oct-18, Volume: 7, Issue:42

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cel

2016
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Oncotarget, 2017, Jan-31, Volume: 8, Issue:5

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Female; Gene Expression Regulation,

2017
Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture.
    Cancer letters, 2010, Jun-28, Volume: 292, Issue:2

    Topics: 3T3 Cells; Animals; Brain Neoplasms; Cell Adhesion; Cell Movement; Glioma; Humans; Hydroxamic Acids;

2010
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
    The Journal of thoracic and cardiovascular surgery, 2010, Volume: 139, Issue:5

    Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezo

2010
Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids.
    Cancer, 2010, Jun-01, Volume: 116, Issue:11 Suppl

    Topics: Antineoplastic Agents; Breast Neoplasms; Cadherins; Cell Aggregation; Cell Division; Cell Line, Tumo

2010
Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
    PloS one, 2011, Volume: 6, Issue:8

    Topics: Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromatin;

2011
Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.
    The Journal of biological chemistry, 2006, Mar-03, Volume: 281, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogens; Carrier Proteins; Cell Differentiation; Cell

2006